Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
51.34 (1y: +38%)
Market Cap 52.88 B P/E(ttm) 15.20
Enterprise Value 62.03 B P/B 3.00
MDT- NYSE (USA)
Medtronic, Inc.
  • Currently 3.5/5
Business Predictability Rank: 3.5-Star
Back Testing Results:
Average gain of all 3.5-Star stocks: 9.3% per year.
% of Stocks that are in still loss if held for 10yrs: 9%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$51.34
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyÂ’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry		 vs
history
Cash to Debt 0.244
MDT's Cash to Debt is ranked lower than
80% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 3750.67 vs. MDT: 0.244 )
MDT' s 10-Year Cash to Debt Range
Min: 0.21   Max: 7.76
Current: 0.24
0.21
7.76
Equity to Asset 0.137
MDT's Equity to Asset is ranked lower than
82% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 0.53 vs. MDT: 0.137 )
MDT' s 10-Year Equity to Asset Range
Min: 0.08   Max: 0.61
Current: 0.14
0.08
0.61
Interest Coverage 31.3
MDT's Interest Coverage is ranked higher than
50% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 420.30 vs. MDT: 31.3 )
MDT' s 10-Year Interest Coverage Range
Min: 13   Max: No Debt
Current: 31.3
F-Score: 5
Z-Score: 3.51
M-Score: -2.69
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyÂ’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry		 vs
history
Operating margin (%) 28.80
MDT's Operating margin (%) is ranked higher than
90% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 5.80 vs. MDT: 28.80 )
MDT' s 10-Year Operating margin (%) Range
Min: 17.8   Max: 34.6
Current: 28.8
17.8
34.6
Net-margin (%) 22.3
MDT's Net-margin (%) is ranked higher than
87% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 3.25 vs. MDT: 22.3 )
MDT' s 10-Year Net-margin (%) Range
Min: 11.3   Max: 22.8
Current: 22.3
11.3
22.8
ROE (%) 21.1
MDT's ROE (%) is ranked higher than
85% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 4.80 vs. MDT: 21.1 )
MDT' s 10-Year ROE (%) Range
Min: 12.8   Max: 27.1
Current: 21.1
12.8
27.1
ROA (%) 10.9
MDT's ROA (%) is ranked higher than
75% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 3.40 vs. MDT: 10.9 )
MDT' s 10-Year ROA (%) Range
Min: 9   Max: 19.4
Current: 10.9
9
19.4
ROC (Joel Greenblatt) (%) 68.40
MDT's ROC (Joel Greenblatt) (%) is ranked higher than
90% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 14.00 vs. MDT: 68.40 )
MDT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 47.7   Max: 115.2
Current: 68.4
47.7
115.2
Revenue Growth (%) 4.1
MDT's Revenue Growth (%) is ranked higher than
78% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. MDT: 4.1 )
MDT' s 10-Year Revenue Growth (%) Range
Min: 4.1   Max: 13.1
Current: 4.1
4.1
13.1
EBITDA Growth (%) 15.3
MDT's EBITDA Growth (%) is ranked higher than
89% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: -1.10 vs. MDT: 15.3 )
MDT' s 10-Year EBITDA Growth (%) Range
Min: -2.1   Max: 23.4
Current: 15.3
-2.1
23.4
EPS Growth (%) 15.3
MDT's EPS Growth (%) is ranked higher than
88% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 2.10 vs. MDT: 15.3 )
MDT' s 10-Year EPS Growth (%) Range
Min: -2   Max: 19.3
Current: 15.3
-2
19.3
» MDT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

MDT Guru Trades in Q2 2012

Jim Simons 1,625,300 sh (New)
Paul Tudor Jones 5,700 sh (New)
Pioneer Investments 112,728 sh (+1397.45%)
Chuck Royce 64,655 sh (+39.78%)
Manning & Napier Advisors, Inc 449,222 sh (+24.39%)
Bill Nygren 3,670,000 sh (+19.54%)
Diamond Hill Capital 5,759,853 sh (+7.47%)
Jeff Auxier 156,970 sh (+2.61%)
Joel Greenblatt 63,169 sh (+1.83%)
Steven Cohen 408,600 sh (+1.6%)
Scott Black 21,241 sh (+1.51%)
Bill Frels 3,691,005 sh (+1.44%)
Dodge & Cox 11,313,719 sh (+0.36%)
John Keeley 49,190 sh (unchged)
John Hussman 1,501,200 sh (unchged)
Whitney Tilson 40,000 sh (unchged)
Tom Russo 2,100 sh (unchged)
Zeke Ashton 50,000 sh (unchged)
Jean-Marie Eveillard 8,000 sh (unchged)
Vanguard Health Care Fund 10,901,100 sh (unchged)
Meridian Funds 12,500 sh (unchged)
Donald Yacktman 400,000 sh (unchged)
George Soros Sold Out
Arnold Van Den Berg 325,098 sh (-0.61%)
James Barrow 29,465,389 sh (-0.75%)
HOTCHKIS & WILEY 904,326 sh (-1.43%)
Chris Davis 411,193 sh (-3.25%)
PRIMECAP Management 40,288,409 sh (-6.96%)
Ray Dalio 109,900 sh (-9.99%)
Jeremy Grantham 7,628,972 sh (-16.08%)
Ken Fisher 60,541 sh (-99.31%)
» More
Q3 2012

MDT Guru Trades in Q3 2012

Chuck Royce 76,730 sh (+18.68%)
John Hussman 1,751,200 sh (+16.65%)
Bill Nygren 3,870,000 sh (+5.45%)
Paul Tudor Jones 5,900 sh (+3.51%)
Manning & Napier Advisors, Inc 455,560 sh (+1.41%)
Pioneer Investments 113,803 sh (+0.95%)
Bill Frels 3,710,855 sh (+0.54%)
James Barrow 29,587,754 sh (+0.42%)
John Keeley 49,300 sh (+0.22%)
Yacktman Fund 400,000 sh (unchged)
Jean-Marie Eveillard 8,000 sh (unchged)
Meridian Funds 12,500 sh (unchged)
Tom Russo 2,100 sh (unchged)
Vanguard Health Care Fund 10,901,100 sh (unchged)
Donald Yacktman 400,000 sh (unchged)
Zeke Ashton Sold Out
Ray Dalio Sold Out
Jim Simons Sold Out
Whitney Tilson Sold Out
HOTCHKIS & WILEY 895,206 sh (-1.01%)
Jeff Auxier 154,970 sh (-1.27%)
Scott Black 20,881 sh (-1.69%)
Arnold Van Den Berg 318,433 sh (-2.05%)
Dodge & Cox 10,983,119 sh (-2.92%)
PRIMECAP Management 39,062,999 sh (-3.04%)
Diamond Hill Capital 5,561,490 sh (-3.44%)
Chris Davis 393,984 sh (-4.19%)
Jeremy Grantham 7,158,312 sh (-6.17%)
Joel Greenblatt 53,141 sh (-15.87%)
Steven Cohen 290,015 sh (-29.02%)
Ken Fisher 40,421 sh (-33.23%)
» More
Q4 2012

MDT Guru Trades in Q4 2012

Ray Dalio 221,345 sh (New)
Yacktman Focused Fund 400,000 sh (New)
Pioneer Investments 328,721 sh (+188.85%)
Joel Greenblatt 152,490 sh (+186.95%)
Paul Tudor Jones 13,100 sh (+122.03%)
HOTCHKIS & WILEY 1,586,440 sh (+77.22%)
Chuck Royce 90,180 sh (+17.53%)
Bill Nygren 3,985,000 sh (+2.97%)
Bill Frels 3,753,342 sh (+1.14%)
John Keeley 49,370 sh (+0.14%)
Jean-Marie Eveillard 8,000 sh (unchged)
Jeremy Grantham 7,231,664 sh (unchged)
Yacktman Fund 400,000 sh (unchged)
Vanguard Health Care Fund 10,801,100 sh (unchged)
Donald Yacktman 400,000 sh (unchged)
Jeff Auxier 154,520 sh (-0.29%)
James Barrow 29,373,065 sh (-0.73%)
Vanguard Health Care Fund 10,801,100 sh (-0.92%)
Scott Black 20,619 sh (-1.25%)
Arnold Van Den Berg 308,748 sh (-3.04%)
Diamond Hill Capital 5,283,518 sh (-5%)
Dodge & Cox 10,365,919 sh (-5.62%)
John Hussman 1,652,400 sh (-5.64%)
PRIMECAP Management 36,713,969 sh (-6.01%)
Manning & Napier Advisors, Inc 423,663 sh (-7%)
Chris Davis 366,212 sh (-7.05%)
Ken Fisher 19,248 sh (-52.38%)
Steven Cohen 84,233 sh (-70.96%)
Tom Russo 200 sh (-90.48%)
» More
Q1 2013

MDT Guru Trades in Q1 2013

Paul Tudor Jones 21,300 sh (+62.6%)
Jeremy Grantham 8,427,751 sh (+16.54%)
Diamond Hill Capital 6,060,438 sh (+14.7%)
HOTCHKIS & WILEY 1,787,590 sh (+12.68%)
Bill Frels 4,165,327 sh (+10.98%)
Chuck Royce 96,000 sh (+6.45%)
Bill Nygren 4,185,000 sh (+5.02%)
James Barrow 30,813,326 sh (+4.9%)
Scott Black 20,894 sh (+1.33%)
Pioneer Investments 329,620 sh (+0.27%)
Jeff Auxier 154,770 sh (+0.16%)
Tom Russo 200 sh (unchged)
Vanguard Health Care Fund 10,801,100 sh (unchged)
Jean-Marie Eveillard 8,000 sh (unchged)
Yacktman Focused Fund Sold Out
Donald Yacktman Sold Out
Yacktman Fund Sold Out
John Keeley 49,070 sh (-0.61%)
Arnold Van Den Berg 303,503 sh (-1.7%)
Chris Davis 351,745 sh (-3.95%)
Dodge & Cox 9,936,393 sh (-4.14%)
Manning & Napier Advisors, Inc 392,911 sh (-7.26%)
PRIMECAP Management 32,434,321 sh (-11.66%)
Joel Greenblatt 129,842 sh (-14.85%)
Ray Dalio 165,445 sh (-25.25%)
Ken Fisher 11,133 sh (-42.16%)
John Hussman 503,300 sh (-69.54%)
Steven Cohen 13,315 sh (-84.19%)
» More
» Details

Insider Trades

Latest Guru Trades with MDT

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Hussman 2013-03-31 Reduce -69.54%1.25%$41.02 - $47.22 $ 51.5314%503300
Yacktman Focused Fund 2013-03-31 Sold Out 0.26%$41.02 - $47.22 $ 51.5314%0
Yacktman Fund 2013-03-31 Sold Out 0.23%$41.02 - $47.22 $ 51.5314%0
James Barrow 2013-03-31 Add 4.9%0.12%$41.02 - $47.22 $ 51.5314%30813326
Donald Yacktman 2013-03-31 Sold Out 0.1%$41.02 - $47.22 $ 51.5314%0
Ray Dalio 2013-03-31 Reduce -25.25%0.02%$41.02 - $47.22 $ 51.5314%165445
Yacktman Focused Fund 2012-12-31 New Buy0.26%$40.75 - $44.67 $ 51.5322%400000
Joel Greenblatt 2012-12-31 Add 186.95%0.23%$40.75 - $44.67 $ 51.5322%152490
Ray Dalio 2012-12-31 New Buy0.09%$40.75 - $44.67 $ 51.5322%221345
John Hussman 2012-09-30 Add 16.65%0.26%$37.35 - $43.47 $ 51.5328%1751200
Ray Dalio 2012-09-30 Sold Out 0.06%$37.35 - $43.47 $ 51.5328%0
George Soros 2012-06-30 Sold Out 0.06%$35.89 - $39.39 $ 51.5337%0
Premium More recent guru trades are included for Premium Members only!!

Guru Investment Theses on Medtronic, Inc.

Diamond Hill Capital Comments on Medtronic Inc - Oct 24, 2012

Medical device manufacturer Medtronic, Inc. (MDT) reported results that were in-line with Wall Street analysts' expectations but demonstrated sequential improvement in underlying trends, including sales growth excluding foreign exchange affects. Medtronic's growth prospects benefited from market share gains in the Drug-eluting Stent (DES) business, with a better than expected launch of the Resolute Integrity stent. A focus on the international opportunities, specifically China, should also improve long-term potential.

From Diamond Hill Capital's third quarter Select Fund Commentary.


Check out Diamond Hill Capital latest stock trades

Top Ranked Articles about Medtronic, Inc.

Diamond Hill Capital Update and Top Three
May 14, 2013
Diamond Hill - Diamond Hill Capital Update And Top Three
Founded in year 2000, Diamond Hill Capital Management lists assets under management of $10.7 billion, as of April 30, 2013. Independent and publicly owned, Diamond Hill is listed on Nasdaq (DHIL) and included in the Russell 2000 Index. Led by Corporate CEO Ric Dillon, Diamond Hill manages five long-only equity strategies, three alternative equity strategies and a fixed income strategy. Here's an update on Diamond Hill Capital’s top three holdings and how those companies are performing in the first quarter of 2013: Read more...
Why Cooperman and Price Are Betting on Boston Scientific’s Turnaround
December 31, 2012
Leon Cooperman - Why Cooperman And Price Are Betting On Boston Scientific’s Turnaround
Boston Scientific(BSX) is a worldwide developer, manufacturer, and marketer of less-invasive medical devices used in a broad range of interventional medical specialties. The company has always prided itself on its continuing development of medical innovations aimed at raising standards, reducing costs, increasing efficiency, and providing faster recovery times for patients. Leon Cooperman and Michael Price have positions in Boston Scientific (BSX), one of the stock market’s most heart-breaking companies in the last few years. The company’s strengths are evident in its strong growth platform of products, a favorable price reflected in its low P/B ratio, a positive direction taken by new management, and aging populations around the world. Read more...
Diamond Hill Capital Comments on Medtronic Inc
October 24, 2012
Medical device manufacturer Medtronic, Inc. (MDT) reported results that were in-line with Wall Street analysts' expectations but demonstrated sequential improvement in underlying trends, including sales growth excluding foreign exchange affects. Medtronic's growth prospects benefited from market share gains in the Drug-eluting Stent (DES) business, with a better than expected launch of the Resolute Integrity stent. A focus on the international opportunities, specifically China, should also improve long-term potential. Read more...
Weekly Top Insider Buys: MDT, KMI, WIN, ENDP, OC
June 25, 2012
According to GuruFocus Insider Data, these are the largest insider buys during the past week: Medtronic Inc. (MDT), Kinder Morgan Energy Partners L.P. (KMI), Windstream Corp. (WIN), Endo (ENDP) and Owens Corning (OC). Read more...

Ratios

vs
industry		 vs
history
P/E(ttm) 15.30
MDT's P/E(ttm) is ranked higher than
87% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 24.10 vs. MDT: 15.30 )
MDT' s 10-Year P/E(ttm) Range
Min: 9.85   Max: 76.46
Current: 15.3
9.85
76.46
P/B 3.05
MDT's P/B is ranked lower than
58% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 1.99 vs. MDT: 3.05 )
MDT' s 10-Year P/B Range
Min: 2.05   Max: 15.99
Current: 3.05
2.05
15.99
P/S 3.24
MDT's P/S is ranked lower than
72% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 1.70 vs. MDT: 3.24 )
MDT' s 10-Year P/S Range
Min: 1.92   Max: 14.36
Current: 3.24
1.92
14.36
PFCF 12.21
MDT's PFCF is ranked higher than
80% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 18.60 vs. MDT: 12.21 )
MDT' s 10-Year PFCF Range
Min: 9.46   Max: 250
Current: 12.21
9.46
250
EV-to-EBIT 12.99
MDT's EV-to-EBIT is ranked higher than
95% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 16.25 vs. MDT: 12.99 )
MDT' s 10-Year EV-to-EBIT Range
Min: 7.5   Max: 47.8
Current: 12.99
7.5
47.8
PEG 1.46
MDT's PEG is ranked higher than
98% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 1.23 vs. MDT: 1.46 )
MDT' s 10-Year PEG Range
Min: 0.94   Max: 50.29
Current: 1.46
0.94
50.29
Shiller P/E 18.12
MDT's Shiller P/E is ranked higher than
92% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 23.60 vs. MDT: 18.12 )
MDT' s 10-Year Shiller P/E Range
Min: 12.1   Max: 51.14
Current: 18.12
12.1
51.14

Dividend & Buy Back

vs
industry		 vs
history
Dividend Yield 2.02
MDT's Dividend Yield is ranked higher than
87% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 1.71 vs. MDT: 2.02 )
MDT' s 10-Year Dividend Yield Range
Min: 0.28   Max: 2.93
Current: 2.02
0.28
2.93
Dividend Payout 0.4
MDT's Dividend Payout is ranked higher than
90% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 0.55 vs. MDT: 0.4 )
MDT' s 10-Year Dividend Payout Range
Min: 0.18   Max: 0.39
Current: 0.4
0.18
0.39
Dividend growth (3y) 6.6
MDT's Dividend growth (3y) is ranked higher than
96% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 6.50 vs. MDT: 6.6 )
MDT' s 10-Year Dividend growth (3y) Range
Min: 6.6   Max: 18.1
Current: 6.6
6.6
18.1
Yield on cost (5-Year) 4.26
MDT's Yield on cost (5-Year) is ranked higher than
98% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 1.76 vs. MDT: 4.26 )
MDT' s 10-Year Yield on cost (5-Year) Range
Min: 0.6   Max: 6.23
Current: 4.26
0.6
6.23
Share Buyback Rate 1.5
MDT's Share Buyback Rate is ranked higher than
94% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: -1.05 vs. MDT: 1.5 )
MDT' s 10-Year Share Buyback Rate Range
Min: 2   Max: -0.8
Current: 1.5

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 13.9
MDT's Price/Net Current Asset Value is ranked higher than
78% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 8.90 vs. MDT: 13.9 )
MDT' s 10-Year Price/Net Current Asset Value Range
Min: 10.8   Max: 50.4
Current: 13.9
10.8
50.4
Price/Tangible Book 11.5
MDT's Price/Tangible Book is ranked higher than
90% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 3.80 vs. MDT: 11.5 )
MDT' s 10-Year Price/Tangible Book Range
Min: 8.9   Max: 41.3
Current: 11.5
8.9
41.3
Price/DCF (Projected) 1
MDT's Price/DCF (Projected) is ranked higher than
78% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 1.25 vs. MDT: 1 )
MDT' s 10-Year Price/DCF (Projected) Range
Min: 0.8   Max: 2.6
Current: 1
0.8
2.6
Price/Median PS Value 0.6
MDT's Price/Median PS Value is ranked higher than
56% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 0.80 vs. MDT: 0.6 )
MDT' s 10-Year Price/Median PS Value Range
Min: 0.5   Max: 2.4
Current: 0.6
0.5
2.4
Price/Peter Lynch Fair Value 2.3
MDT's Price/Peter Lynch Fair Value is ranked lower than
67% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 2.10 vs. MDT: 2.3 )
MDT' s 10-Year Price/Peter Lynch Fair Value Range
Min: 1.1   Max: 3
Current: 2.3
1.1
3
Price/Graham Number 2.8
MDT's Price/Graham Number is ranked higher than
88% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 1.80 vs. MDT: 2.8 )
MDT' s 10-Year Price/Graham Number Range
Min: 2.2   Max: 10.1
Current: 2.8
2.2
10.1
Earnings Yield (Greenblatt) 7.70
MDT's Earnings Yield (Greenblatt) is ranked higher than
97% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 5.95 vs. MDT: 7.70 )
MDT' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.1   Max: 13.3
Current: 7.7
2.1
13.3
Forward Rate of Return (Yacktman) 15.47
MDT's Forward Rate of Return (Yacktman) is ranked higher than
88% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 3.03 vs. MDT: 15.47 )
MDT' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 2.9   Max: 26.7
Current: 15.47
2.9
26.7

Business Description

Medtronic, Inc. was founded in 1949 and was incorporated as a Minnesota corporation in 1957. It is engaged in medical technology- alleviating pain, restoring health, and extending life for millions of people around the world. The Company provides innovative products and therapies for use by medical professionals to meet the healthcare needs of their patients. Its primary products include those for cardiac rhythm disorders, cardiovascular disease, neurological disorders, spinal conditions and musculoskeletal trauma, urological and digestive disorders, diabetes and ear, nose and throat conditions. The Company currently functions in seven operating segments that manufacture and sell device-based medical therapies. Its operating segments are: Cardiac Rhythm Disease Management (CRDM), Spinal, CardioVascular, Neuromodulation, Diabetes, Surgical Technologies and Physio-Control. CRDM is a supplier of medical devices for cardiac rhythm disease management. The Company's Spinal business is a supplier for innovative medical devices and implants used in the treatment of the spine. Its CardioVascular business offers a line of minimally invasive products and therapies to treat coronary artery disease, abdominal and thoracic aortic aneurysms, peripheral vascular disease and heart valve disorders. Its Neuromodulation business develops, manufactures and markets devices for the treatment of neurological, urological and gastroenterological disorders. The Company's Diabetes business develops advanced diabetes management solutions. It provides integrated diabetes management systems, insulin pump therapy, continuous glucose monitoring systems and therapy management software. Its Surgical Technologies business develops, manufactures, and markets products and therapies to treat diseases and conditions of the ear, nose and throat (ENT), and certain neurological disorders. In addition, the segment manufactures and markets image guided surgery and intra-operative imaging systems that facilitate surgical planning during precision cranial, spinal, sinus and orthopedic surgeries. The Company's Physio-Control products are used in the treatment of Sudden Cardiac Arrest (SCA), which is a condition in which the heartbeat stops suddenly and unexpectedly. The Company's primary customers include hospitals, clinics, third party healthcare providers, distributors, and other institutions, including governmental healthcare programs and group purchasing organizations. It sells its medical devices through direct sales representatives in the U.S. and a combination of direct sales representatives and independent distributors in international markets. The three largest markets for its medical devices are the U.S., Western Europe and Japan. The Company competes in both the therapeutic and diagnostic medical markets in more than 120 countries throughout the world. In the product lines in which it competes, it faces a mixture of competitors ranging from large manufacturers with
Company Website
SEC Reports
Industry: Medical Devices
Compare:SYK, SMA, ZMH, STJ, EW
Traded in other countries:MDT.Germany
» More Articles for MDT

Headlines

Articles On GuruFocus.com
Diamond Hill Capital Update and Top Three May 14 2013 
Attractively valued dividend stocks to consider today May 14 2013 
My 4 Favorite Dividend Aristocrats with Highest Profitability May 07 2013 
20 Dividend Champions with Highest 10-Year Dividend Growth Rates Apr 24 2013 
Busy Selling - Yacktman Focused Fund First Quarter Apr 12 2013 
Yacktman Fund - Texas Billionaire Guru Adds and Sells First Quarter Apr 12 2013 
How Much Money Will You Need Before Retiring? Mar 06 2013 
Early Movers for Tuesday Feb. 19, 2013 Feb 19 2013 
My 3 Favorites of the 20 Most-Recommended Dividend Champions Dec 31 2012 
Why Cooperman and Price Are Betting on Boston Scientific’s Turnaround Dec 31 2012 

More From Our Partners
UPDATE: Oppenheimer Raises PT on Medtronic Following Solid FQ4 Sales May 22 2013 - BENZINGA

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial